Diffuse leptomeningeal melanocytosis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

4 events
Nov 2025Gentle Touch for Post-Mastectomy Lymphedema

I.R.C.C.S. Fondazione Santa Lucia — PHASE4

TrialRECRUITING
Sep 20256 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

Wuhan Pulmonary Hospital — NA

TrialNOT YET RECRUITING
Jun 2022Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB

Boston University — PHASE2

TrialRECRUITING
Aug 1997

AmBisome: FDA approved

Treatment of visceral leishmaniasis.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

AmBisome

Fujisawa USA, Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

AmBisome

(Liposomal amphotericin B)Orphan drug

Fujisawa USA, Inc.

Lipid-based Polyene Antifungal [EPC]

Approved Aug 1997FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Diffuse leptomeningeal melanocytosis.
Search all trials →
Search clinical trials for Diffuse leptomeningeal melanocytosis

Recent News & Research

No recent news articles indexed yet for Diffuse leptomeningeal melanocytosis.
Search PubMed for Diffuse leptomeningeal melanocytosis

Browse all Diffuse leptomeningeal melanocytosis news →

Specialist Network

Top 6 by expertise

View all Diffuse leptomeningeal melanocytosis specialists →

Quick Actions